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Rational
Neurally adjust ventilatory assist (NAVA) is a ventilatory
mode that tailors the level of assistance delivered by the
ventilator to the electromyographic activity of the dia-
phragm. Physiological studies have demonstrated the
benefit of NAVA on patient ventilator interactions and
prevention of lung over inflation. However, clinical data
are currently lacking.
Objectives
To compare NAVA and Pressure Support Ventilation
(PSV) at the early phase of ventilator weaning in patients
recovering from an acute respiratory failure.
Patients and Methods
A multicenter randomized controlled trial of 128 intu-
bated adults (median [IQR] age, 66 [57-77] years) was
conducted in 11 intensive care units in France from
April 2010 to June 2012. Patients were included as soon
as they could tolerate PSV with a PS level ≤30 cmH2O,
a PEEP ≤8 cmH2O and a FiO2 ≤50%. Patients were ran-
domly assigned to NAVA (n = 62) or PSV (n = 66). The
PS level in the PSV group and the NAVA level in the
NAVA group were set to obtain a tidal volume of 6-8
ml/kg. The primary end point was the probability to
remain in an assist mode during the entire first 48
hours. Secondary end points were duration of mechani-
cal ventilation and 28 days mortality.
Results
67.2% (n = 45) in the NAVA group vs. 63.3% (n = 44)
in the PSV group (p = 0.66).. The time spend in an
assist mode during the first 48 hours was 47 [43-48]
hours in the NAVA group vs. 47 [40-48] hours in the
PSV group (p = 0.55). The asynchrony index was
lower in the NAVA group (19.7% vs. 32.6%), so was
the prevalence of dyspnea at day-1 (9% vs. 19%). The
time to first extubation was 7 [2-10] days in the
NAVA group vs. 7 [2-10] days in the PSV group (p =
0.78). The hospital mortality rate in the NAVA group
was 14.5% (n = 9) vs. 21.2% (n = 14) in the PSV group
(p = 0.2). NAVA and PSV were associated to similar
oxygenation. NAVA was not associated with any
adverse event.
Conclusions
NAVA can be applied efficiently in a clinical setting and
improves patient ventilator interaction. However, NAVA
does not increase the probability to remain in an
assisted mode nor it reduces hospital mortality.
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